Fig. 6: Identification of the composition of commercially available medicinal grade GM1 using the MOCECA strategy.

a HRMS spectrum for a commercial GM1 drug named Sygen™. b HRMS spectrum for glycosphingosine products of MOCECA-synthesized GM1 analogs mixed with GM1 (d18:1/C18:0) and GM1 (d20:1/C18:0) hydrolyzed by SA_SCD. c HRMS spectrum for glycosphingosine products of MOCECA-synthesized GM1 analogs mixed with GM1 (d18:1/C18:0) and GM1 (d18:1/C20:0) hydrolyzed by SA_SCD. d HRMS spectrum for glycosphingosine products of Sygen™ hydrolyzed by SA_SCD.